More 80s Bruce Springsteen Songs - Top 10 Bruce Springsteen Songs of the 80s, Part 2

Early Childhood Development Lakeland Little Learners

Lakeland Little Learners Early childhood development is one of the most important aspects to the human life. Early childhood is mainly referred to from the time of birth through age five. Although, children learn based on the influence of their familiar environment, every child is expected to develop in their own unique way. Lakeland Little Learners is an educational program that provides an excellent environment for ensuring that every child’s social, cognitive, physical and educational needs are met. LLL provides a very welcoming and caring atmosphere for children from ages two weeks to twelve years old. During my experience at LLL, I was able to sit and observe three classrooms with very different age groups of children. Upon†¦show more content†¦While sitting and observing circle time I noticed that the children were very directed. They all sat quietly and listened to the teacher. Before speaking they knew to raise their hands and they were called upon before spea king. If perhaps a student spoke without being called on they were redirected as they coped with that very well. After starting with the 4K program, I then went to the late three’s room. In the late three’s room, I noticed a lot of the same activities going on however the behavior was much different. The arriving schedule was very similar for both three and four year olds. Just as the 4K room the kids arrived and began the day with circle time following hanging their coats and washing hands. One of the differences I noticed during circle time was the attention span was much shorter with the three year olds. Many of the kids where getting up often and wandering off to different play areas, pushing one another, and interrupting when the teacher was talking. Once they were redirected there was some crying and attitude unlike the four year olds who took direction fairly well. Once disciplined I noticed that the child would wander off and sit by him/her self. Some differenc es I noticed in the learning activities where: the threes focused only on the first letter of

Blood Transfusion Free Essays

BIOPURE INDUSTRIESA Marketing Analysis Based on the data from the case study by Jonn Gourville, Biopure Corporation , HBS, 1998April 20, 2005By Veronica Stepanova Executive  Summary†¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦ 2 Situation AnalysisI. Human  Market†¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦.. We will write a custom essay sample on Blood Transfusion or any similar topic only for you Order Now 3II. Animal  Market†¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦.. 5 Marketing Plan  for oxyglobin†¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦. 6 Final  decision†¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦ 7 Appendix 1 A (Excel documents, separate attachment) Appendix 1 B Executive Summary Many opportunities are available in the human blood market due to several disadvantages of thecurrently available alternatives. Even more opportunities exist in the  animal blood market. †¢Oxyglobin should be positioned as a high-quality product designed for middle- to upper-classbudgets. †¢The price for Oxyglobin should be about $200 for the consumer and around $100 for the supplier(animal hospital) to account for distribution markups and other  carrying costs. †¢Distribution should be oriented in the regional  vicinity of the operation and implement largerclinics. In addition, only emergency clinics are to be targeted. Current opportunities are favorable for Oxyglobin’s launch. Situation Analysis I. Human blood market. †¢Patients with acute blood loss from  trauma  and surgery – 40% individuals aged 65+. †¢Chronic anemia  patients (any age) – 1. 5 million for the year 1995. †¢Blood loss, resulting from trauma (e. g. car accident) and exceeding 2-3 units (1 unit = 10% of  total blood content of human body) needs immediate  blood transfusion. †¢Price is largely cost-based (storage, implementation) – blood donation is free. Existing options. †¢Red  blood cells  and their components (hemoglobin, platelets, and plasma) are  collected viadonations, organized by blood collection centers and  then transfused into patients. †¢Current options allow for storage for 6  weeks in refrigerated conditions, consequently disposed of  if unused. Hemoglobin uses oxygen-carrying efficiency by 50% if not used  within the first few weeks. †¢Blood transfusion is subject to blood typing (A, B,  AB, O, positive, negative) andreception/rejection by the body. Incorrect matching may be fatal  for the patient. Infection risks slow down the process of  testing blood prior to its use and are  greater if blood isnot separated into components. Infections include the risks of AIDS, hepatitis B,  and contamination. †¢Blood transfusion is available on-site only (hospital or emergency room); as a  result, 30% traumapatients die prior to operation. †¢Blood supply is lower than demand, esp ecially during peak periods (summer  months and winterholidays, during which car and other travel increases ? fewer donors and more patients). Blood substitutes. †¢3 companies in final stages awaiting FDA  approval (clinical testing). Entrance into market is difficult (all current processes patented) and  time-consuming – may takeup to 17 years (See case Exhibit 3). Potential to replace current blood drawing process by  component separation and purification, aswell as chemical modification and stabilization of hemoglobin. Reduced risk of contamination and increased storage capability of 2 years. Added benefits for patients with constricted or restricted blood vessels (smaller size improvedaccessibility to organs). Possibility of adapting animal blood cells for use in  humans. Risk of toxicity and body rejection (sped up  excretion). Competitors/industry players .A. Baxter   Northfield Laboratories. †¢Both rely on human blood supply to  derive hemoglo bin. †¢Red blood cells obtained from expired banks. †¢Require refrigeration. Baxter: †¢Leader in development and manufacturing of blood-oriented medical equipment. †¢Large facility – production capacity of 1 million units/year, spent $250  million on RD. †¢Product – HemAssist – to be  priced between $600-$800. Northfield: †¢Small facility –  10,000-unit production capability but possible expansion into  300,000 units/year. Focus on single product (PolyHeme), $70 million spent on development. B. Biopure Corporation. †¢Specializes in protein purification for pharmaceutical use. †¢Hemopure 2 years away from final approval. †¢Derived from the blood of cattle. †¢Production capacity of 150,000 but  possible production limitations due to expected concurrentusage of production equipment for animal version. †¢Need for removal of  hemoglobin clusters from product? excess process in  production abi lity. †¢Cost for Biopure at $1. 50 per unit of animal blood, but plan to match Baxter’s price for finalconsumer product. II. Animal blood market. †¢Mainly cats (35%) and dogs (50%). †¢800 dogs were brought to emergency  treatment due to acute blood loss in 1995,  2. 5% severe. Existing options. †¢15,000 veterinary clinics. †¢5% of vet clinics perform emergency care, with a 75% referral rate from primary care  clinics. †¢Current blood banks insufficient, demand greatly exceeds supply: 2. 5 out of 30  cases treated. †¢93% blood drawn from donor animals (78%  in emergencies) – an ethically questionable practice. †¢150 units of blood transfused per emergency care, 17 per  primary care center (Appendix A). No effective blood typing or cross-matching systems. †¢Blood collection, storage, and transfusion too costly for proper operation. †¢Current cost of clinical care  to animal owners relatively high, undesirable. ? 84% doctor dissatisfaction with current alternatives. Blood substitutes. †¢Biopure’s Oxyglobin currently the only exi sting  FDA-approved substitute ready for launch. †¢No evident chemical difference in the  production process between animal and human supplement. †¢Animal supplement approved sooner than human equivalent due to less-strict regulations in theanimal consumer market. Production capacity of 300,000 units, $200 million spent on development (combined withHemopure) Marketing Plan for OxyglobinPositioning strategy. Most animal owners (enthusiasts) can be  assumed to be within the middle to  upperincome class, based on the extraneous costs of owning an animal (refer to case Exhibit 8 for a summary of  average costs of keeping a  pet). However, many consumers proved to be  price-conscious about spendingadditional funds on optional services (this will be analyzed further in the  pricing strategy); therefore, nopremium strategy should be used. The product should be positioned as  a high-quality supplement forblood transfusion, available to (affordable by) most animal owners. Pricing strategy. As cited, animal  owners expect to spend limited amounts of money on  animal care; thisis slightly different for emergency situations, where customers are willing to spend more,  as demonstratedby the survey results (Exhibit 8; Table B). The typical cost of a  blood transfusion to the customer iscurrently $100 for the traditional method; however, this price was  said to have been cost-unjustified. Still,veterinarians were cited as the  trusted source for determining a patient’s treatment selection, which putspressure on the new substitute segment to set  a competitive price standard. While profit margins mayprove higher on a higher-priced item, the  product’s sensitivity to reputation for being a supposedlyâ€Å"better, cheaper alternative† to currently available options, which would satisfy the currently largely-unfulfilled demand for blood transfusion, would pressure Biopure to price its Oxyglobin according tocustomer expectations (See â€Å"Existing options†, page 5 of this report). Those expectations, as  we can seefrom the attached appendix (Appendix 1 A and B), are that the price to the consumer be about $200 ($100to the veterinarian – keeping the  50% markup), which would give the company the largest  marginal gainin revenues (higher prices are actually marginal  losses! ), while still retaining the major demand (weconsider emergency care centers more important here,  since they have, proportionally, a much largerdemand than primary care centers). In terms of the  price difference between Oxyglobin and its competitorin the human segment, Baxter, the latter spent $50 million more on RD than Biopure, so the pricepremium on Baxter can be  justified by higher costs; in addition, Biopure’s per-unit costs are significantlysmaller because it uses cattle blood. In addition, Biopure may price Hemopure slightly higher because of  the extra processing that goes into making it,  as well as the variation in  the segment and target audience(people are willing to spend more on  themselves than on animals). Distribution. Biopure should only target emergency care  practices. Although those only make up 5% of  the overall industry, 75% primary care specialists will refer  an acute blood loss case (such as a trauma)  toone of these centers. Furthermore, Biopure should target large practices (3+ doctors) through regionaldistributors, both of which account for the largest sales in  the industry. Considering the limited volume of  supplies Biopure is going to have, a  national distribution may not be desirable right away, until thecompany at least increases its production capabilities. A regional distributor would be local enough tounderstand the specific needs of its market (e. g. , New England), and a larger vet practice could provemore efficient (and less costly) in  terms of the availability of materials and  the reduction of transfers,thereby also reducing the consumer’s costs and increasing the rate  of success by providing a quicker  service (in other words, it would have more  cases, but more doctors available to  help overall, fewercases per doctor – see Exhibit 7). Of course, the drawback is that a large clinic would not be as personal. The 1 million dollar question: Should Oxyglobin be launched? – Yes. †¢Launching early allows for an audience test:? Achieve acclaim/recognition for a break-through discovery that is beneficial because it-Fulfills an unsatisfied/dissatisfied need (better quality blood  transfusion, availability);-Reduces costs to both suppliers and consumers.? Easier entry into secondary (human) market –  Ã¢â‚¬Å"tested on animals† – more trusted  than untestedcompetitors.? Potential to utilize production to full potential (instead of splitting up with Hemopure); later on, dividebased on larger per-unit profit (and  not necessarily the stated 150:300 ratio).? If fails or doesn’t test well: – Would aid in the decision about improving current human version (complete discontinuation notan option due to  the immense initial investment in RD);- Reduce the shock of having to change both formulas (processes) simultaneously – longer timespan gives better flexibility and more time for testing and improvement – less drastic. Hemopure and Oxyglobin,  although similar in purposes, are meant for two completelydifferent segments; they should not be compared based on price because price expectations aredifferent for humans than they are  for animal needs; the demand for Oxyglobin  is clear andsignificant, while the demand for the same product in the human market is questionable. Therefore, stick with Oxyglobin – which alrea dy has the approval – and launch it. How to cite Blood Transfusion, Essay examples

Blood Transfusion Free Essays

BIOPURE INDUSTRIESA Marketing Analysis Based on the data from the case study by Jonn Gourville, Biopure Corporation , HBS, 1998April 20, 2005By Veronica Stepanova Executive  Summary†¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦ 2 Situation AnalysisI. Human  Market†¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦.. We will write a custom essay sample on Blood Transfusion or any similar topic only for you Order Now 3II. Animal  Market†¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦.. 5 Marketing Plan  for oxyglobin†¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦. 6 Final  decision†¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦Ã¢â‚¬ ¦ 7 Appendix 1 A (Excel documents, separate attachment) Appendix 1 B Executive Summary Many opportunities are available in the human blood market due to several disadvantages of thecurrently available alternatives. Even more opportunities exist in the  animal blood market. †¢Oxyglobin should be positioned as a high-quality product designed for middle- to upper-classbudgets. †¢The price for Oxyglobin should be about $200 for the consumer and around $100 for the supplier(animal hospital) to account for distribution markups and other  carrying costs. †¢Distribution should be oriented in the regional  vicinity of the operation and implement largerclinics. In addition, only emergency clinics are to be targeted. Current opportunities are favorable for Oxyglobin’s launch. Situation Analysis I. Human blood market. †¢Patients with acute blood loss from  trauma  and surgery – 40% individuals aged 65+. †¢Chronic anemia  patients (any age) – 1. 5 million for the year 1995. †¢Blood loss, resulting from trauma (e. g. car accident) and exceeding 2-3 units (1 unit = 10% of  total blood content of human body) needs immediate  blood transfusion. †¢Price is largely cost-based (storage, implementation) – blood donation is free. Existing options. †¢Red  blood cells  and their components (hemoglobin, platelets, and plasma) are  collected viadonations, organized by blood collection centers and  then transfused into patients. †¢Current options allow for storage for 6  weeks in refrigerated conditions, consequently disposed of  if unused. Hemoglobin uses oxygen-carrying efficiency by 50% if not used  within the first few weeks. †¢Blood transfusion is subject to blood typing (A, B,  AB, O, positive, negative) andreception/rejection by the body. Incorrect matching may be fatal  for the patient. Infection risks slow down the process of  testing blood prior to its use and are  greater if blood isnot separated into components. Infections include the risks of AIDS, hepatitis B,  and contamination. †¢Blood transfusion is available on-site only (hospital or emergency room); as a  result, 30% traumapatients die prior to operation. †¢Blood supply is lower than demand, esp ecially during peak periods (summer  months and winterholidays, during which car and other travel increases ? fewer donors and more patients). Blood substitutes. †¢3 companies in final stages awaiting FDA  approval (clinical testing). Entrance into market is difficult (all current processes patented) and  time-consuming – may takeup to 17 years (See case Exhibit 3). Potential to replace current blood drawing process by  component separation and purification, aswell as chemical modification and stabilization of hemoglobin. Reduced risk of contamination and increased storage capability of 2 years. Added benefits for patients with constricted or restricted blood vessels (smaller size improvedaccessibility to organs). Possibility of adapting animal blood cells for use in  humans. Risk of toxicity and body rejection (sped up  excretion). Competitors/industry players .A. Baxter   Northfield Laboratories. †¢Both rely on human blood supply to  derive hemoglo bin. †¢Red blood cells obtained from expired banks. †¢Require refrigeration. Baxter: †¢Leader in development and manufacturing of blood-oriented medical equipment. †¢Large facility – production capacity of 1 million units/year, spent $250  million on RD. †¢Product – HemAssist – to be  priced between $600-$800. Northfield: †¢Small facility –  10,000-unit production capability but possible expansion into  300,000 units/year. Focus on single product (PolyHeme), $70 million spent on development. B. Biopure Corporation. †¢Specializes in protein purification for pharmaceutical use. †¢Hemopure 2 years away from final approval. †¢Derived from the blood of cattle. †¢Production capacity of 150,000 but  possible production limitations due to expected concurrentusage of production equipment for animal version. †¢Need for removal of  hemoglobin clusters from product? excess process in  production abi lity. †¢Cost for Biopure at $1. 50 per unit of animal blood, but plan to match Baxter’s price for finalconsumer product. II. Animal blood market. †¢Mainly cats (35%) and dogs (50%). †¢800 dogs were brought to emergency  treatment due to acute blood loss in 1995,  2. 5% severe. Existing options. †¢15,000 veterinary clinics. †¢5% of vet clinics perform emergency care, with a 75% referral rate from primary care  clinics. †¢Current blood banks insufficient, demand greatly exceeds supply: 2. 5 out of 30  cases treated. †¢93% blood drawn from donor animals (78%  in emergencies) – an ethically questionable practice. †¢150 units of blood transfused per emergency care, 17 per  primary care center (Appendix A). No effective blood typing or cross-matching systems. †¢Blood collection, storage, and transfusion too costly for proper operation. †¢Current cost of clinical care  to animal owners relatively high, undesirable. ? 84% doctor dissatisfaction with current alternatives. Blood substitutes. †¢Biopure’s Oxyglobin currently the only exi sting  FDA-approved substitute ready for launch. †¢No evident chemical difference in the  production process between animal and human supplement. †¢Animal supplement approved sooner than human equivalent due to less-strict regulations in theanimal consumer market. Production capacity of 300,000 units, $200 million spent on development (combined withHemopure) Marketing Plan for OxyglobinPositioning strategy. Most animal owners (enthusiasts) can be  assumed to be within the middle to  upperincome class, based on the extraneous costs of owning an animal (refer to case Exhibit 8 for a summary of  average costs of keeping a  pet). However, many consumers proved to be  price-conscious about spendingadditional funds on optional services (this will be analyzed further in the  pricing strategy); therefore, nopremium strategy should be used. The product should be positioned as  a high-quality supplement forblood transfusion, available to (affordable by) most animal owners. Pricing strategy. As cited, animal  owners expect to spend limited amounts of money on  animal care; thisis slightly different for emergency situations, where customers are willing to spend more,  as demonstratedby the survey results (Exhibit 8; Table B). The typical cost of a  blood transfusion to the customer iscurrently $100 for the traditional method; however, this price was  said to have been cost-unjustified. Still,veterinarians were cited as the  trusted source for determining a patient’s treatment selection, which putspressure on the new substitute segment to set  a competitive price standard. While profit margins mayprove higher on a higher-priced item, the  product’s sensitivity to reputation for being a supposedlyâ€Å"better, cheaper alternative† to currently available options, which would satisfy the currently largely-unfulfilled demand for blood transfusion, would pressure Biopure to price its Oxyglobin according tocustomer expectations (See â€Å"Existing options†, page 5 of this report). Those expectations, as  we can seefrom the attached appendix (Appendix 1 A and B), are that the price to the consumer be about $200 ($100to the veterinarian – keeping the  50% markup), which would give the company the largest  marginal gainin revenues (higher prices are actually marginal  losses! ), while still retaining the major demand (weconsider emergency care centers more important here,  since they have, proportionally, a much largerdemand than primary care centers). In terms of the  price difference between Oxyglobin and its competitorin the human segment, Baxter, the latter spent $50 million more on RD than Biopure, so the pricepremium on Baxter can be  justified by higher costs; in addition, Biopure’s per-unit costs are significantlysmaller because it uses cattle blood. In addition, Biopure may price Hemopure slightly higher because of  the extra processing that goes into making it,  as well as the variation in  the segment and target audience(people are willing to spend more on  themselves than on animals). Distribution. Biopure should only target emergency care  practices. Although those only make up 5% of  the overall industry, 75% primary care specialists will refer  an acute blood loss case (such as a trauma)  toone of these centers. Furthermore, Biopure should target large practices (3+ doctors) through regionaldistributors, both of which account for the largest sales in  the industry. Considering the limited volume of  supplies Biopure is going to have, a  national distribution may not be desirable right away, until thecompany at least increases its production capabilities. A regional distributor would be local enough tounderstand the specific needs of its market (e. g. , New England), and a larger vet practice could provemore efficient (and less costly) in  terms of the availability of materials and  the reduction of transfers,thereby also reducing the consumer’s costs and increasing the rate  of success by providing a quicker  service (in other words, it would have more  cases, but more doctors available to  help overall, fewercases per doctor – see Exhibit 7). Of course, the drawback is that a large clinic would not be as personal. The 1 million dollar question: Should Oxyglobin be launched? – Yes. †¢Launching early allows for an audience test:? Achieve acclaim/recognition for a break-through discovery that is beneficial because it-Fulfills an unsatisfied/dissatisfied need (better quality blood  transfusion, availability);-Reduces costs to both suppliers and consumers.? Easier entry into secondary (human) market –  Ã¢â‚¬Å"tested on animals† – more trusted  than untestedcompetitors.? Potential to utilize production to full potential (instead of splitting up with Hemopure); later on, dividebased on larger per-unit profit (and  not necessarily the stated 150:300 ratio).? If fails or doesn’t test well: – Would aid in the decision about improving current human version (complete discontinuation notan option due to  the immense initial investment in RD);- Reduce the shock of having to change both formulas (processes) simultaneously – longer timespan gives better flexibility and more time for testing and improvement – less drastic. Hemopure and Oxyglobin,  although similar in purposes, are meant for two completelydifferent segments; they should not be compared based on price because price expectations aredifferent for humans than they are  for animal needs; the demand for Oxyglobin  is clear andsignificant, while the demand for the same product in the human market is questionable. Therefore, stick with Oxyglobin – which alrea dy has the approval – and launch it. How to cite Blood Transfusion, Essay examples

Cleopatra A Hellenistic Ruler of Egypt free essay sample

She is undoubtedly one of the most famous persons of her time and there is a huge amount of evidence to support how she has shaped the Ancient world. In her lifetime Cleopatra was able to achieve a lot more then what was expected of her as she was a female ruler in a time when men dominated and shaped the Ancient world as ruler of Egypt. Cleopatra had a heavy influence on the Roman Empire and played a crucial part in the power struggle of the Octavian’s. However Cleopatra’s significants extends beyond the grave, she was able to achieve what she had always wanted: to keep her legend alive and form a symbol of female sexuality and power. In her lifetime Cleopatra was able to accomplish many great things as ruler of Egypt . As she was a female ruler she was not well accepted by most as she lived in a period where men where superior to females. We will write a custom essay sample on Cleopatra: A Hellenistic Ruler of Egypt or any similar topic specifically for you Do Not WasteYour Time HIRE WRITER Only 13.90 / page At the time Cleopatra was ruling there was a growing interest in the Egyptian empire as both Roman and Egyptian forces where fighting for its ownership. Cleopatra was able to keep the political structure of the empire together and ensured the Ptolemaic dynasty continued, however her death lead to the downfall of the Egyptian Empire as the Roman rule of Caesar Augustus’s began. Cleopatra was significant to the Ancient world as she was able to use her sexuality, persuasiveness and seductive abilities to influence her reign and impact as Queen of Egypt. This can be seen through her relationships with Julius Caesar and Mark Antony two of the most influential figures in the Roman Empire at the time. According to the Historian Cassius Dio, Caesar â€Å"was spellbound the moment he set eyes on her† (Cassius D, 1986 p35). It has been recorded by many historians that Cleopatra was incredibly beautiful. Archaeological evidence found in Thebes of toilet boxes and other various make up products suggest that Cosmetics were basically invented by Egyptians. Cleopatra used these products to enhance her beauty and appearance which would have made her more attractive then most Roman females. It was through her relationships with Caesar and Mark Antony and surpassable beauty that Cleopatra was able to gain power as ruler, effectively increasing her significance to a study of the Ancient World.